BioIVT is contributing to four healthcare organizations this year, focusing on cancer, liver diseases, Alzheimer’s disease, and global health equity
Westbury, NY – Dec. 1, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is making several charitable donations in December to honor its clients' commitment to medical research.
Cambridge, United Kingdom – 1 December 2020 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, is pleased to announce the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer (CCO), effective immediately. Muthu will lead all aspects of Congenica’s sales and marketing and will be based in Boston, MA.
Global executive search and interim management specialist, Horton International UK, is delighted to announce the appointment of Emma Whittle as Partner within its Global Healthcare arm.
Emma brings to the team over 20 years’ experience within search and talent acquisition, built across a range of industries and with significant emphasis on hiring for the life sciences sectors, including technology digitalisation, medical technology and diagnostics.
A biotech start-up, whose technology aims to tackle cornea
donor tissue shortages and speed up life-changing transplants worldwide, has moved into a specialist lab facility – The Biosphere on Newcastle Helix.
Cambridge 26th November 2020: The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups - ArkVax, Paediatric HealthTech, ConcR and Stroma Biosciences - went head-to-head on Wednesday afternoon (Nov 25th); competing for £10,000 additional funding generously donated by CMS Ventures in the Accelerate@Babraham with AstraZeneca: Start-up Pitching Competition.
o2h ventures is delighted to announce the launch of their HMRC approved knowledge intensive EIS fund, focussing on supporting the expansion of UK research and development in biotech therapeutics and AI.
To support the Government’s aim to strengthen and grow UK innovation, which were known to be capital and research intensive, the EIS knowledge intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas.
AMSBIO offer a wide range of Heparan Sufate antibodies, enzymes, standards and ready-to-use Heparanase activity assays for researchers seeking to better understand COVID-19 and thereby to combat the pandemic.
SOMERSET, N.J. – November 23, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
CAMBRIDGE UK, 16 November 2020:
Start Codon, a life science and healthcare business accelerator based in Cambridge, UK, today announced that it has closed Start Codon Fund I LP (the “Fund”) at £15 million. The Fund will be used to support Start Codon’s offering to start-ups, which includes a minimum of £250K seed funding, business support services, expert guidance, and access to cutting-edge office and lab facilities. Limited Partner ("LP") investors in the Fund include Novartis International AG and Cambridge Innovation Capital.